30 results
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
, and multiple external IVIg/PE datasets Use all available global data and ü Routinely engaged with leading experts in GBS routinely seek expert input ü
8-K
EX-99.1
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
datasets Use all available global data and ✓ Routinely engaged with leading experts in GBS routinely seek expert input ✓ Proportional odds uses full
DEF 14A
dnlh7 gxif0
22 Apr 21
Definitive proxy
4:06pm
10-K
dxozcjyujc6p
25 Mar 21
Annual report
7:16am
8-K
EX-10.1
eef27s 4q
22 Dec 20
Entry into a Material Definitive Agreement
4:05pm
424B4
aob5 7dux0xnzy5qj
24 Jul 20
Prospectus supplement with pricing info
5:15pm
S-1/A
xwfs5v5en r26
20 Jul 20
IPO registration (amended)
6:07am
S-1/A
EX-10.11
7b4ylxiu5n
20 Jul 20
IPO registration (amended)
6:07am
CORRESP
ro0ibwqu844
14 Jul 20
Correspondence with SEC
12:00am
S-1
EX-10.3
uj4st900f5b41 xrmu
2 Jul 20
IPO registration
12:00am
S-1
EX-10.7
itvuxzw77ik4fiizl5f4
2 Jul 20
IPO registration
12:00am
S-1
EX-10.8
bplcq
2 Jul 20
IPO registration
12:00am